A5025392392- HER2/EGFR in Cancer Research
- Monoclonal and Polyclonal Antibodies Research
- Cancer Cells and Metastasis
- Cancer Research and Treatments
- Melanoma and MAPK Pathways
- Cell Adhesion Molecules Research
- Glycosylation and Glycoproteins Research
- Peptidase Inhibition and Analysis
- Nanoplatforms for cancer theranostics
- Click Chemistry and Applications
- Sarcoma Diagnosis and Treatment
Pfizer (United States)
2024-2025
Seagen (United States)
2019-2023
SGN-CD228A is an investigational antibody-drug conjugate (ADC) directed to melanotransferrin (CD228, MELTF, MFI2, p97), a cell-surface protein first identified in melanoma. consists of humanized antibody, hL49, with high specificity and affinity for CD228 that stably conjugated 8 molecules the clinically validated microtubule-disrupting agent monomethyl auristatin E (MMAE) via novel glucuronide linker. We performed comprehensive IHC studies, which corroborated published RNA sequencing data...
Abstract MFI2, also known as CD228, melanotransferrin, p97, MTf, or MELTF, is a GPI-anchored membrane protein that belongs to the iron-transporting transferrin family. CD228 expression elevated in multiple solid tumors such melanoma and non-small cell lung cancer (NSCLC) but has limited normal tissues. Here, we have expanded our analysis found other tumors, including head neck (HNSCC) esophageal (ESCC), show positivity rates of 86% 94%, respectively. PF-08046031 an antibody-drug conjugate...
Integrins are a large family of cell surface receptors with diverse roles in cellular adhesion, motility, and cytokinesis. Functional integrins exist as heterodimers consisting single alpha beta chains. Within this family, integrin beta-6 (IB6), which dimerizes exclusively alpha-v, is target interest the clinic for its role cancer. IB6 expression low normal adult epithelial tissues high solid tumors. In some cases, has been demonstrated to be associated poor prognosis such non-small lung,...
<h3>Background</h3> Effective cancer treatment requires durable elimination of malignant cells. Cytotoxic chemotherapeutic agents used to treat often show initial anti-tumor efficacy, but fail produce long-term responses in patients. The elicitation and improved survival response cytotoxic may be associated with the induction innate adaptive immune cancer. For example, tumor cells undergoing apoptosis following exposure some emit immunostimulatory damage-associated molecular patterns...
<h3>Background</h3> Sigvotatug vedotin (SV, formerly SGN-B6A) is an antibody-drug conjugate (ADC) comprised of the antibody, h2A2, which binds to integrin-β6 (IB6). IB6 exclusively integrin-αv and functions as heterodimer αvβ6. SV conjugated clinically validated payload monomethyl auristatin E (MMAE). Beyond its role in driving tumor intrinsic pathways oncogenesis invasiveness, αvβ6 regulates activation latent transforming growth factor-β (TGFβ) by binding latency associated protein (LAP)...
Abstract SGN-B6A is a novel investigational antibody-drug conjugate (ADC) directed to integrin beta-6 and uses the clinically validated vedotin drug-linker platform that delivers microtubule disrupting agent, monomethyl auristatin E (MMAE). designed bind internalize beta-6/ADC complex from surface of malignant cells release cytotoxic payload MMAE. We have previously demonstrated antitumor activity in cell line-derived xenograft models originating multiple carcinomas as well patient-derived...
Abstract Melanotransferrin (CD228/MFI2/MELTF) is a cell-surfaced glycosylphosphatidylinoitol (GPI)-anchored glycoprotein that belongs to the transferrin family of iron-binding proteins. CD228 was first described as an oncofetal protein highly expressed on malignant melanoma cells. Data from The Cancer Genome Atlas (TCGA) suggests has broad expression across many types carcinomas and it recently potential biomarker invasive colorectal carcinoma. In this study, we characterize using...
Melanotransferrin (CD228/MFI2/MELTF) is a cell-surfaced glycosylphosphatidylinoitol (GPI)-anchored glycoprotein that belongs to the transferrin family of iron-binding proteins. CD228 was first described as an oncofetal protein highly expressed on malignant melanoma cells. Data from The Cancer Genome Atlas (TCGA) suggests has broad expression across many types carcinomas and it recently potential biomarker invasive colorectal carcinoma. In this study, we characterize using immunohistochemical...
<p>Antibody humanization, binding assays, conjugation, mass spec, additional in vivo details</p>
<p>Figures S1-S9</p>
<p>Figures S1-S9</p>
<div>Abstract<p>SGN-CD228A is an investigational antibody–drug conjugate (ADC) directed to melanotransferrin (CD228, MELTF, MFI2, p97), a cell-surface protein first identified in melanoma. SGN-CD228A consists of humanized antibody, hL49, with high specificity and affinity for CD228 that stably conjugated 8 molecules the clinically validated microtubule-disrupting agent monomethyl auristatin E (MMAE) via novel glucuronide linker. We performed comprehensive IHC studies, which...
<div>Abstract<p>SGN-CD228A is an investigational antibody–drug conjugate (ADC) directed to melanotransferrin (CD228, MELTF, MFI2, p97), a cell-surface protein first identified in melanoma. SGN-CD228A consists of humanized antibody, hL49, with high specificity and affinity for CD228 that stably conjugated 8 molecules the clinically validated microtubule-disrupting agent monomethyl auristatin E (MMAE) via novel glucuronide linker. We performed comprehensive IHC studies, which...
<p>Antibody humanization, binding assays, conjugation, mass spec, additional in vivo details</p>
<p>Figures S1-S9</p>
<p>Antibody humanization, binding assays, conjugation, mass spec, additional in vivo details</p>
<p>Figures S1-S9</p>
<p>Antibody humanization, binding assays, conjugation, mass spec, additional in vivo details</p>
<div>Abstract<p>SGN-CD228A is an investigational antibody–drug conjugate (ADC) directed to melanotransferrin (CD228, MELTF, MFI2, p97), a cell-surface protein first identified in melanoma. SGN-CD228A consists of humanized antibody, hL49, with high specificity and affinity for CD228 that stably conjugated 8 molecules the clinically validated microtubule-disrupting agent monomethyl auristatin E (MMAE) via novel glucuronide linker. We performed comprehensive IHC studies, which...
Abstract Patient-derived xenograft (PDX) models are widely recognized as a powerful preclinical tool. In contrast to cell line-derived (CDX) models, patient tumors excised and implanted directly into mice such, retain tumor characteristics that often lost in lines. Multiple studies have shown PDX similar histology, genetic mutations, gene expression patterns actual samples. Additionally, they reflect diversity of both disease stage treatment history, enabling an assessment how these factors...